Tagworks Pharmaceuticals

Primary contact
Toernooiveld 1
6525 ED Nijmegen
Netherlands
+31 85 800 8550
Toernooiveld 1
6525 ED Nijmegen
Netherlands
+31 85 800 8550
Diseases & Conditions Cancer
Sections Biopharmaceuticals
Funding π°
Total $65M
Select investors Ysios Capital, Gilde Healthcare, New Enterprise Associates, Novartis Venture Fund, BIF Partners, Lightstone Ventures, Meneldor, OostNL
Key people π§βπ€βπ§
- Marc Robillard, PhD - Co-founder & CEO
- Jay Feingold, MD, PhD - Chief Medical Officer
- Luc Schmitt - CFO
- Wendy Lin - VP of Development & Regulatory Affairs
- Raffaella Rossin, PhD - Co-founder & Head of Discovery
- Zach Taylor, MBA - Co-founder & VP and Global Head of Corporate Development & Strategy @ BioNTech SE
Highlights β
- Patent-protected tech: A key patent encompassing the therapeutic application scope of the Click-to-Release platform has been granted in the US, further strengthening Tagworks' IP portfolio. The patent titled "BIO-ORTHOGONAL DRUG ACTIVATION" protects a broad scope of TCO linkers and tetrazine activators and their application in selective on-target release and activation of a wide range of constructs, including small molecule prodrugs, antibody-drug conjugates, and caged proteins. π
- Expanding the ADC target scope: Tagworks Pharmaceuticals is leveraging its Click-to-Release approach to expand the ADC (antibody-drug conjugate) target scope to non- or poorly internalizing receptors and markers. It also enables controlled drug release with a broad bystander effect that makes it possible to kill tumors with heterogenous target expression. π
- Nobel-prized tech: Tagworks Pharmaceuticals is the pioneer of the technology known as Click-to-Release, and the first company built to utilize this therapeutic approach. Click-to-Release was developed based on the 2022 Nobel Prize winning research of Carolyn Bertozzi, Morten Meldal and Barry Sharpless, as well as on the foundational work of Joseph Fox (University of Delaware). π
In the news π°
Awards & Recognitions π
- 2019 World ADC Award for Best Publication
Quotes π¬
“
We are proud to have assembled such a strong, international syndicate of investors around Tagworks. Click-to-Release shows tremendous potential to bring forward a new generation of biologic therapeutics with higher efficacy and improved safety that could be very meaningful for patients. We look for companies with truly differentiated approaches, and thus we are delighted to support Tagworks in its next phase of development.
— Thomas Harth, Principal at Ysios Capital π
“
Tagworks' cutting-edge technology platform is very promising for the development of first and best in class therapeutics, such as ADCs, immunomodulators and radiopharmaceuticals. The ability to enable on-target activation or off-target deactivation is a potentially game-changing opportunity in the field of drug development. We look forward to working closely with this top-tier team as it advances powerful new treatments for cancer and other diseases.
— Edwin de Graaf, Managing Partner at Gilde Healthcare π
Last update: June 28, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more